Literature DB >> 28598139

Mini-sling efficacy in obese versus non-obese patients for treatment of stress urinary incontinence.

Matteo Frigerio1,2, Cristina Regini3, Stefano Manodoro4, Federico Spelzini1,5, Rodolfo Milani1,2.   

Abstract

BACKGROUND: The impact of obesity on single-incision has been object of concerns. The aim of the study was to compare the outcomes of MiniArc single-incision sling in normal weight, overweight and obese patients.
METHODS: This retrospective study analyzed women with proven stress urinary incontinence (SUI). Patients were divided into three groups according to BMI: normal weight (group A), overweight (group B) and obese (group C). Objective cure rate was assessed with stress test and subjective cure rate was determined by ICIQ-SF and PGI-I scores. Postoperative overactive bladder syndrome and voiding symptoms were recorded.
RESULTS: One hundred ninety-two patients were analyzed (A=97; B=68; C=27). Mean follow-up was 23.2 months without differences among groups. Estimated blood loss and operative time were not influenced by BMI. No bladder perforation were observed. Objective cure rate (A=87.6%; B=86.8%; C=81.5%) and subjective outcomes resulted similar irrespective of BMI class. De novo onset of overactive bladder syndrome and voiding symptoms were reported without significant differences among groups.
CONCLUSIONS: The current study showed that single-incision sling Miniarc seems to be an effective treatment irrespective of BMI. Operative data, complications, objective and subjective outcomes were similar for normal weight, overweight and obese women.

Entities:  

Mesh:

Year:  2017        PMID: 28598139     DOI: 10.23736/S0026-4784.17.04081-3

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  1 in total

1.  Single-incision slings for the treatment of stress urinary incontinence: efficacy and adverse effects at 10-year follow-up.

Authors:  Matteo Frigerio; Rodolfo Milani; Marta Barba; Luca Locatelli; Giuseppe Marino; Gianluca Donatiello; Federico Spelzini; Stefano Manodoro
Journal:  Int Urogynecol J       Date:  2020-09-09       Impact factor: 2.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.